- Poster presentation
- Open Access
Role of NIHR HTA clinical trials on subsequent systematic reviews
© Raftery and Young 2015
Published: 16 November 2015
The Health Technology Assessment programme relies partly on systematic reviews for the identification of topics for the commissioning of clinical trials. However, the Programme does not examine the extent to which relevant systematic reviews, new or updates, report.
Aims and Objectives
To review the HTA portfolio of published trials to determine the extent to which HTA funded trials are included in subsequent systematic reviews.
A cohort of published HTA trials to December 2011 (from the metadata HTA project) were reviewed. The Cochrane Library was searched for reviews containing HTA funded trials using the technology and disease as search terms.
The preliminary findings from the Cochrane Library found 28 trials out of the eligible 121 trials (excluding four pilot and feasibility studies) were found in a subsequent Cochrane systematic review. The weight of the included HTA trials varied widely (from 100% to 9%). In eight reviews, the trial had a weight of 100% indicating how the trial provided the only evidence for that particular comparison. However, of those 28 trials, only half showed superiority. For the rest, the 95% confidence interval included a measure of no difference. The implications of this will be discussed.
The HTA Programme completes one side of a loop from a systematic review to the need for a new trial but not vice versa. The impact of a new trial on the subsequent systematic review is not examined. Only by completing this side of the loop can it be established whether further research is required.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.